Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Working Capital Changes (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Other Working Capital Changes for 8 consecutive years, with -$1.4 million as the latest value for Q1 2026.

  • For Q1 2026, Other Working Capital Changes rose 51.08% year-over-year to -$1.4 million; the TTM value through Mar 2026 reached -$3.6 million, up 91.68%, while the annual FY2025 figure was -$5.0 million, 87.72% up from the prior year.
  • Other Working Capital Changes hit -$1.4 million in Q1 2026 for Kymera Therapeutics, down from -$1.3 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $16.8 million in Q3 2022 and bottomed at -$44.1 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is -$5.5 million, with a median of -$358000.0 recorded in 2023.
  • On a YoY basis, Other Working Capital Changes climbed as much as 917.91% in 2022 and fell as far as 8472.99% in 2022.
  • Kymera Therapeutics' Other Working Capital Changes stood at -$37.0 million in 2022, then soared by 129.37% to $10.9 million in 2023, then plummeted by 505.62% to -$44.1 million in 2024, then surged by 96.99% to -$1.3 million in 2025, then decreased by 2.18% to -$1.4 million in 2026.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$1.4 million, -$1.3 million, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.